Palifermin

Palifermin is a first-in-class investigational compound in development by Amgen for oral mucositis (mouth sores).

Palifermin will be the first therapy indicated to reduce the incidence, duration and severity of oral mucositis in bone marrow transplant patients.

Palifermin helped protect patients from the most severe form of oral mucositis (grade 4) with 20 percent of palifermin-treated patients experiencing this painful and debilitating side effect, compared to 62 percent of placebo-treated patients.